The company, which develops drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, has a market cap of $1.60 billion.The largest guru shareholder of the company is Lee Ainslie (Trades, Portfolio)'s Maverick Capital with 0.98% of outstanding shares, followed by Greenblatt with 0.21% and Jones with 0.17%.